Abstract
Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-old man with complete right atelectasis was diagnosed with squamous cell carcinoma (SCC) of the right lower lobe (tumor proportion score: TPS 90%, cT4N3M0, stage 3C). For first-line chemotherapy, carboplatin and nab-paclitaxel were effective for the primary lesion and the right lung atelectasis improved. However, due to repeated febrile neutropenia with pneumonia, treatment was modified to pembrolizumab monotherapy. Bronchoscopic rebiopsy prior to second-line treatment revealed high TPS, with a severe stenosis in the right main bronchus. After three courses of pembrolizumab, the right main bronchus opened completely, and no signs of malignancy were observed. Bronchoscopic narrow-band and autofluorescence imaging also confirmed a complete endobronchial response. Subsequent bronchoscopic observation two years after the initial diagnosis showed a complete and continued response to treatment. ICIs can result in a drastic...Continue Reading
References
May 17, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Masako ChiyoTakehiko Fujisawa
Nov 20, 2012·Annual Review of Immunology·Guido KroemerLaurence Zitvogel
Jul 31, 2013·Immunity·Daniel S Chen, Ira Mellman
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 14, 2017·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Gary X WangFlorian J Fintelmann
Apr 17, 2018·The New England Journal of Medicine·Patrick M FordeDrew M Pardoll
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Feb 20, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Marcelo V NegraoJianjun Zhang